What is Anthrax Vaccines Market?
Anthrax is a serious disease that can affect both animals and humans caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides. There are three types of anthrax including cutaneous anthrax, gastrointestinal anthrax and inhalation anthrax. The anthrax vaccine is used to protect against anthrax disease. The factors such as Increasing Incidences of Anthrax Disease and Rise in the Number of Hospitals and Clinics are driving the global anthrax vaccine market.
The market study is being classified by Type (Live Vaccines and Cell free PA Vaccines), by Application (Human Use and Animal Use) and major geographies with country level break-up.
Porton Biopharma Limited (United Kingdom), Colorado Serum Co (United States), Emergent BioSolutions Inc. (United States), Boehringer Ingelheim Animal Health (France), Merck & Co. (United States), Zoetis Inc. (United States), Bayer (Germany), Colorado Serum Co (United States), PharmAthene, Inc. (United States) and Tiankang (China) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Biogenesis Bago SA (Argentina) and Instituto Rosenbusch SA (Argentina).
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Anthrax Vaccines market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Anthrax Vaccines market by Type, Application and Region.
On the basis of geography, the market of Anthrax Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Incidences of Anthrax Disease
- Rise in the Number of Hospitals and Clinics
- Advancements in the Medical Science
- Robust Increase in the Distribution Channels
- Side Effects of the Anthrax Vaccine
- Growth in the Health Care Industry Worldwide
- Increased Healthcare Infrastructure in Developing Countries
- Stringent Government Rules and Regulations
Recently, NanoBio Corporation has announced the progression of a novel intranasal anthrax vaccine into a pre-clinical IND-enabling toxicology study funded by the U.S. National Institute of Health's National Institute of Allergy and Infectious Diseases (NIAID). The vaccine combines NanoBio's novel intranasal nanoemulsion (NE) adjuvant with recombinant protective antigen (rPA) for anthrax from Porton Biopharma Ltd (PBL).
Key Target AudienceAnthrax Vaccines Manufacturers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase